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Background. Prediabetes is a preclinical stage in the hyperglycemia continuum where subjects are at increased risk of developing
diabetes. Several studies reported a positive association between markers of sleep-disordered breathing (SDB) and diabetes.
However, few studies investigated the relationship between SDB markers and prediabetes. Methods. We examined 5,685
participants ≥20 years from the National Health and Nutrition Examination Survey (NHANES) 2005–2008. The exposure of
interest was SDB markers including sleep duration, snoring, snorting, and daytime sleepiness. The outcome was prediabetes
(n = 2058), among subjects free of diabetes. Results. SDB markers were associated with prediabetes. Compared to those without
any sleep disturbance, the multivariable odds ratio (OR) (95% confidence interval (CI)) of prediabetes among those with three or
more SDB markers was 1.69 (1.28–2.22). In subgroup analyses, the association between SDB markers and prediabetes was stronger
among women (OR (95% CI) = 2.09 (1.36–3.23) when compared to men (1.52 (1.00–2.35)) and was present among non-Hispanic
whites (2.66 (1.92–3.69)) and Mexican Americans (1.99 (1.13–3.48)), but not among non-Hispanic blacks (1.10 (0.70–1.73)).
Conclusion. SDB markers were associated with prediabetes. This association was stronger in women and was present mainly in
non-Hispanic whites and Mexican Americans.
1. Introduction
Sleep-disordered breathing (SDB), a major public health
problem, refers to a group of disorders characterized by
abnormalities of respiratory pattern or the quantity of
ventilation during sleep [1]. It has been estimated that
approximately 12–18 million of US adults are affected by
SDB [2]. On the other hand, prediabetes is a preclinical stage
of diabetes, affecting more than 79 million Americans [3–
5]. Newly identified prediabetes patients usually progress to
type 2 diabetes in less than 3 years [6]. Emerging evidence
suggests that lifestyle and pharmacologic interventions at the
prediabetes stage can prevent or delay the progression into
type 2 diabetes [7–9].
Several studies reported an association between SDB
and an increased risk of diabetes [10–18] and fatal and
nonfatal cardiovascular diseases [17, 19, 20]. However, there
are only few studies investigating the relationship between
markers of SDB and prediabetes [15, 16, 21, 22]. In this
context, we examined the association between several com-
monly accepted markers of SDB including snoring, snorting,
daytime sleepiness, and sleep duration and prediabetes
in a nationally representative sample of US adults after
accounting for age, sex, smoking, alcohol intake, BMI, serum
lipids, and other potential confounders. We also examined
the association between markers of SDB and prediabetes
stratified by gender and race-ethnicity.
2. Methods
The data for this study is derived from the National Health
and Nutrition Examination Survey 2005–2008. Detailed
description of NHANES study design and methods are
available elsewhere [23, 24]. The NHANES survey included
a stratified multistage probability sample representative of
the civilian noninstitutionalized US population. Selection
2 International Journal of Endocrinology
was based on counties, blocks, households, and individuals
within households and included oversampling of non-
Hispanic blacks and Mexican Americans in order to provide
stable estimates of these groups. Out of 20497 participants
in NHANES survey 2005–2008, there were 10914 who were
>20 years of age. We further excluded participants who were
pregnant (n = 393), had prevalent cardiovascular disease
(n = 1275), or have missing information on blood glucose
levels, sleep variables, smoking status, depression, or other
covariates included in the multivariable model. This resulted
in 5685 participants included in the final analysis.
3. Main Outcome of Interest: Prediabetes
Prediabetes was defined as a serum glucose ≥100 mg/dL
and <126 after fasting for a minimum of 8 hours, or a
2-hour oral glucose tolerance test ≥140 and <200 mg/dL
or glycosylated hemoglobin ≥39 (mmoL/moL) and <47.5
(mmoL/moL). Fasting plasma glucose levels were measured
using hexokinase enzymatic method on Roche/Hitachi Mod-
ular P Chemistry Analyzer at the Fairview Medical Center
Laboratory at the University of Minnesota, Minneapolis,
Minnesota. Random plasma glucose levels were measured
at the Collaborative Laboratory Services in Ottumwa, Iowa,
using the Beckman Synchron LX20 in 2007 and the Beckman
Coulter UniCel DxC800 in 2008. Glycosylated hemoglobin
measurements were performed on the Tosoh 2.2 Analyzer
(Tosoh Medics, Inc., 347 Oyster Pt. Blvd., Suite 201, So.
San Francisco, CA 94080) in NHANES 2005-2006 and on
the Automated HPLC System Glycohemoglobin Analyzer
(Tosoh Medics, Inc., 347 Oyster Pt. Blvd., Suite 201, So.San
Francisco, CA 94080) in NHANES 2007-08 at the University
of Minnesota, Minneapolis Minnesota.
4. Assessment of Exposure
Self-reported sleep habits were used to assess SDB, the
exposure of interest. Examples of questions used are “How
much sleep do you usually get at night on weekdays or
workdays?”, “In the past 12 months, how often did you
snore while you were sleeping?”, “In the past 12 months,
how often did you snort, gasp, or stop breathing while you
were asleep?”, and “In the past month, how often did you
feel excessively or overly sleepy during the day?” Based on
the responses to the previous questions, four sleep variables,
sleep duration, snoring, snorting, and daytime sleepiness,
were created. Sleep duration was categorized into ≤5, 6, 7,
8 and ≥9 h. Snoring and snorting variables were categorized
into never or rare, occasional (3-4 nights/week), and frequent
(5 or more nights/week). Daytime sleepiness was categorized
into never or rare, sometimes (2–4 times/month), and often
or almost always (5 or more times/month).
An additive summary SDB score combining all the four
sleep variables was created by dichotomizing the individual
variables based on their clinical significance and previous
literature [18, 25, 26]. A score of 1 was assigned separately
if the participants report sleep duration of ≤5, snoring at
least 3-4 nights/week, snorting at least 3-4 nights/week, and
daytime sleepiness at least 5 times/month. The summary
score ranged from 0 to 4 corresponding to no sleep
disturbance to coexistence of all 4 sleep disturbances.
5. Assessment of Covariates
Information on age, gender, race/ethnicity, smoking status,
alcohol intake (g/day), level of education, and antihyper-
tensive medication use was obtained during a standardized
questionnaire at home interview. Educational attainment
was categorized into less than high school graduate, high
school graduate, and more than high school graduate.
Individuals who had smoked <100 cigarettes during their
lifetime were considered never smokers, those who had
smoked ≥100 cigarettes lifetime and currently not smok-
ing were considered former smokers, and those who had
smoked ≥100 cigarettes lifetime and currently smoking were
considered current smokers. Current alcohol drinking was
defined as consumption of ≥1 alcoholic drink in the past 12
months. Moderate physical activity was defined as engaging
in moderate-intensity sports, fitness, or recreational activities
that cause a small increase in breathing or heart rate such
as brisk walking, bicycling, swimming, or golf for at least
10 minutes continuously in a typical week. Information on
anthropometric, physical, and laboratory components was
obtained during the medical examination center (MEC)
examination. Blood pressure (BP) was measured using
a mercury sphygmomanometer and an average of three
measurements was taken as the systolic and diastolic BP
value. Patients were considered to have hypertension if they
reported taking blood pressure reducing medication and/or
had systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by heights in meter squared. Waist circumfer-
ence was measured in centimeters. Depression was defined as
feeling down, depressed, or hopeless in the past 2 weeks for
more than half of the days or nearly every day.
Detailed description about the blood collection, process-
ing, and quality control checks is provided in the Laboratory
Procedures Manual [23, 27]. Serum C-reactive protein (CRP)
was measured using latex-enhanced nephelometry. Total
serum cholesterol was measured enzymatically using the
Roche Hitachi 717 in 2005, Roche Hitachi 717 and 912 in
2006, and Roche Modular P chemistry analyzer in 2007-
2008.
6. Statistical Analysis
We examined the association between categories of
individual sleep variables, including snoring, snorting,
daytime sleepiness, and sleep duration and prediabetes in
two multivariable models. The first model was adjusted
for age (years) and sex (female, male). The second
model was additionally adjusted for race-ethnicity (non-
Hispanic whites, non-Hispanic blacks, Mexican Americans,
others), education (<high school, high school, >high
school), smoking (never, former, current), current alcohol
consumption (absent, present), moderate physical activity
(times/week), body mass index (kg/m2), waist circumference
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(cm), depression (absent, present), systolic blood pressure
(mmHg), C-reactive protein (mg/dL), total WBC count
(mg/dL), and total cholesterol (mg/dL).
We created an additive summary SDB score and exam-
ined the association between this summary SDB score and
prediabetes. Trends in the odds ratio of prediabetes across
increasing summary SDB score were determined by mod-
eling summary SDB score categories as an ordinal variable.
We also performed subgroup analyses stratified by gender
and race-ethnicity. All analyses were weighted to account
for the unequal probabilities of selection, oversampling, and
nonresponse using SUDAAN (version 8.0; Research Triangle
Institute, Research Triangle Park, NC) and SAS (version 9.1.;
SAS Institute, Cary, NC) software.
7. Results
Table 1 presents the baseline characteristics of the study
population. Among 5685 participants included in the study,
approximately 50% were women. The study population was
primarily white (73.5%). Normal weight, overweight, and
obesity were equally distributed. Mean C-reactive protein
level was 0.36 (±0.01) mg/dL. Prediabetes was present in
approximately 31% of the study subjects.
Table 2 presents the association between markers of SDB
and prediabetes. We found that the SDB-prediabetes asso-
ciation varied among different markers. For sleep duration,
participants who slept either ≤5 hours or 6 hours had
higher odds of prediabetes when compared to those who
slept 7 hours in the age, sex-adjusted model. The multivari-
able adjusted model showed a similar trend, although the
odds ratios were attenuated and failed to reach statistical
significance. For snoring, participants who occasionally or
frequently snored had higher odds of prediabetes when
compared to those who never or rarely snored in the age,
sex adjusted, and the multivariable model. Similarly for
snorting, participants who occasionally or frequently snorted
had higher odds of prediabetes when compared to those who
never or rarely snorted. The age, sex-adjusted odds ratios
were statistically significant. The multivariable adjusted
model showed similar trend, although it failed to reach
statistical significance. For daytime sleepiness, participants
who often and almost always sleep in the daytime did not
have significantly higher odds of prediabetes in the age, sex-
adjusted, or the multivariable-adjusted model.
We also derived an additive summary SDB clustering
score by dichotomizing the SDB variables and taking their
sum, resulting in a score ranging from 0 (no or minimal
markers of sleep disorder) to 4 (cooccurrence of all of the
markers of sleep disorder). For the SDB clustering score,
compared with a score of 0 (referent category), higher
SDB clustering scores were associated with higher odds of
prediabetes. The age, sex-adjusted model as well as the
multivariable-adjusted model were statistically significant.
Table 3 presents the association between prediabetes and
the summary SDB clustering score by gender. The posi-
tive association between higher SDB clustering scores and
prediabetes was still present, showing a stronger association
among women when compared to men.
Table 1: Baseline characteristics of the study population∗.
Characteristics Whole cohort (n = 5685)
Women (%) 2782 (50.6)
Age (years) 43.7± 0.4
Race/ethnicity (%)
Non-Hispanic whites 2898 (73.5)
Non-Hispanic blacks 1085 (9.4)
Mexican Americans 1021 (7.8)
Others 681 (9.3)
Education categories (%)
Below high school 1409 (16.1)
High school 1391 (24.3)
Above high school 2885 (59.5)
Smoking (%)
Never smoker 3045 (52.9)
Former smoker 1284 (22.9)
Current smoker 1356 (24.2)
Current drinker (%) 4056 (76.3)
Moderate physical activity (%) 2741 (54.9)
Body mass index (%)
Normal weight 1869 (35.2)
Overweight 2036 (34.6)
Obese 1780 (30.1)
Depression (%) 348 (5.0)
Systolic blood pressure (mm Hg) 119.7± 0.3
C-reactive protein (mg/dL) 0.358± 0.011
Total cholesterol (mg/dL) 200.74± 0.78
Prediabetes (%) 2058 (31.3)
∗
Data presented are number (percentages) or mean values ± standard error
(SE), as appropriate for the variable.
Table 4 presents the association between prediabetes and
the summary SDB clustering score within various racial
groups. The positive association between higher summary
SDB clustering scores and prediabetes was consistently
present among non-Hispanic Whites and Mexican Ameri-
cans/others but was absent among non-Hispanic Blacks.
To further investigate the role of abdominal obesity, we
ran a supplementary analysis where we additionally adjusted
for waist circumference, in addition to BMI; our results were
essentially similar. In men, compared to those with SDB
summary score of 0 (referent), the multivariable odds ratio
(95% CI) of prediabetes was 1.18 (0.89–1.57) for those with
a score of 1, 1.22 (0.89–1.67) for those with a score of 2, and
1.53 (0.99–2.37) for those with a score of ≥3. Likewise, in
women, compared to those with SDB summary score of 0
(referent), the odds ratio (95% CI) of prediabetes was 1.00
(0.82–1.21) for those with a score of 1, 1.05 (0.80–1.39) for
those with a score of 2, and 1.97 (1.28–3.03) for those with a
score of ≥3.
Also in another supplementary analysis where we addi-
tionally adjusted for total WBC count, another known
biomarker for inflammation in addition to CRP, our results
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≤5 hrs 840 (35.2) 1.40 (1.15–1.71) 1.19 (0.97–1.46)
6 hrs 1332 (34.0) 1.23 (1.03–1.47) 1.17 (0.96–1.42)
7 hrs 1676 (30.0) 1 (referent) 1 (referent)
8 hrs 1485 (29.0) 0.95 (0.78–1.15) 0.94 (0.77–1.14)
≥9 hrs 352 (30.8) 1.13 (0.71–1.81) 1.06 (0.64–1.74)
P-trend 0.005 0.07
Frequency of snoring
Never or rarely 2860 (25.8) 1 (referent) 1 (referent)
Occasionally 1072 (33.8) 1.39 (1.17–1.64) 1.24 (1.04–1.47)
Frequently 1753 (38.5) 1.55 (1.33–1.82) 1.21 (1.02–1.43)
P-trend <0.0001 0.02
Frequency of snorting
Never or rarely 5034 (29.9) 1 (referent) 1 (referent)
Occasionally 341 (41.5) 1.42 (1.05–1.92) 1.24 (0.92–1.68)
Frequently 310 (42.4) 1.51 (1.12–2.04) 1.22 (0.91–1.63)
P-trend 0.001 0.07
Frequency of daytime sleepiness
Never or rarely 3287 (32.0) 1 (referent) 1 (referent)
Sometimes 1482 (30.3) 1.01 (0.84–1.22) 1.00 (0.82–1.21)
Often and almost always 916 (30.9) 1.17 (0.98–1.39) 1.11 (0.92–1.33)
P-trend 0.14 0.37
Sleep summary score
0 2146 (25.8) 1 (referent) 1 (referent)
1 2228 (33.1) 1.34 (1.14–1.57) 1.14 (0.96–1.35)
2 974 (35.4) 1.46 (1.21–1.76) 1.18 (0.97–1.43)
≥3 337 (44.2) 2.32 (1.78–3.04) 1.69 (1.28–2.22)
P-trend <0.0001 0.0007
∗
Adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education (<high
school, high school, >high school), smoking (never, former, current), current alcohol consumption (absent, present), moderate physical activity (times/week),
BMI (kg/m2), depression (absent, present), systolic BP (mm Hg), CRP (mg/dL), and total cholesterol (mg/dL).
were analogous to our previous findings (Table 2). In the
whole cohort, compared to those with a sleep summary score
of 0 (referent), the multivariable odds ratio (95% CI) of
prediabetes was 1.12 (0.94–1.33) for those with a score of 1,
1.16 (0.94–1.42) for those with a score of 2, and 1.66 (1.26–
2.19) for those with a score of ≥3.
8. Discussion
In a multiethnic sample of US adults who were free of
diabetes, we found that markers of SDB including short sleep
duration (≤6 h), occasional or frequent snoring, occasional
or frequent snorting, and frequent daytime sleepiness were
associated with prediabetes in initial age and sex-adjusted
models. However, with multivariable adjustment for possible
confounders, we found that only snoring and snorting were
associated with prediabetes. In subsequent analyses, where
we used an additive summary SDB clustering score as a
measure of the cooccurrence of these SDB markers, we
found that higher SDB clustering score was associated with
higher odds of prediabetes, independent of age, gender, race-
ethnicity, education, smoking, current alcohol consumption,
moderate physical activity, body mass index, depression, sys-
tolic blood pressure, C-reactive protein, and total cholesterol.
In subgroup analyses, the positive association between higher
SDB summary scores and prediabetes showed a stronger
association among women when compared to men and
was consistently present among non-Hispanic whites and
Mexican Americans but was absent among non-Hispanic
blacks.
Prediabetes is a preclinical stage in the hyperglycemia
continuum where subjects are at increased risk of developing
diabetes in the near future [5]. Although several previous
studies reported a positive association between markers of
SDB and diabetes mellitus [10–18], there are few studies
investigating the relationship between markers of SDB and
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0 956 (30.2) 1 (referent) 1 (referent)
1 1180 (36.6) 1.26 (0.99–1.69) 1.18 (0.89–1.57)
2 569 (39.1) 1.43 (1.06–1.93) 1.22 (0.90–1.66)
≥3 198 (44.4) 1.94 (1.29–2.91) 1.52 (1.00–2.35)
P-trend 0.0005 0.05
Women
0 1190 (22.7) 1 (referent) 1 (referent)
1 1048 (29.3) 1.39 (1.15–1.67) 1.05 (0.86–1.29)
2 405 (30.4) 1.50 (1.19–1.89) 1.11 (0.85–1.46)
≥3 139 (44.0) 3.02 (2.00–4.58) 2.09 (1.36–3.23)
P-trend <0.0001 0.009
∗
Adjusted for age (years), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education (<high school, high school,
>high school), smoking (never, former, current), current alcohol consumption (absent, present), moderate physical activity (times/week), BMI (kg/m2),
depression (absent, present), systolic BP (mm Hg), CRP (mg/dL), and total cholesterol (mg/dL).









0 1125 (24.7) 1 (referent) 1 (referent)
1 1111 (31.5) 1.36 (1.11–1.68) 1.19 (0.95–1.49)
2 492 (34.6) 1.56 (1.24–1.97) 1.28 (1.00–1.64)
≥3 170 (43.3) 2.66 (1.92–3.69) 1.92 (1.35–2.72)
P-trend <0.0001 0.0005
Non-Hispanic blacks
0 391 (35.7) 1 (referent) 1 (referent)
1 399 (37.6) 0.95 (0.70–1.30) 0.80 (0.57–1.11)
2 210 (42.0) 1.17 (0.81–1.70) 0.93 (0.62–1.38)
≥3 85 (41.5) 1.10 (0.70–1.73) 0.80 (0.50–1.23)
P-trend 0.39 0.41
Mexican-Americans/others
0 630 (25.9) 1 (referent) 1 (referent)
1 718 (37.2) 1.43 (1.16–1.76) 1.13 (0.91–1.41)
2 272 (34.7) 1.15 (0.78–1.69) 0.90 (0.61–1.32)
≥3 82 (51.1) 1.99 (1.13–3.48) 1.52 (0.85–2.72)
P-trend 0.02 0.49
∗
Adjusted for age (years), sex (men, women), education (<high school, high school, >high school), smoking (never, former, current), current alcohol
consumption (absent, present), moderate physical activity (times/week), BMI (kg/m2), depression (absent, present), systolic BP (mm Hg), CRP (mg/dL), and
total cholesterol (mg/dL).
prediabetes. Among the few studies that have examined the
association between SDB and prediabetes was the Western
New York Study of 364 subjects where only short sleep
duration was associated with prediabetes [22]. However,
these results were inconsistent with other studies where both
short and long sleep durations were positively associated
with impaired glucose tolerance [15, 16, 21]. In the current
study, where we studied a representative sample of US adults,
we found that there was an overall positive association
between markers of SDB and prediabetes, independent of
confounders such as age, BMI, physical activity, and other
factors.
The clinical relevance of our findings is that (1) if these
findings are replicated in future prospective studies, then
interventions to treat SDB may be a novel strategy to prevent
prediabetes, which is a recognized risk factor for diabetes
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[6, 7], as well as cardiovascular disease [28], and chronic
kidney disease [29], and (2) from a risk stratification point
of view, our results support the notion that subjects with
clustering of ≥3 SDB symptoms should be screened for
prediabetes.
In the current study, in subgroup analysis by gender,
SDB was positively associated with prediabetes in both
sexes. However, women showed a stronger association when
compared to men. One explanation for this finding is that the
association in men may be partially explained by factors that
we adjusted in the multivariable model such as BMI, physical
activity, and depression, whereas the association in women
is relatively independent of these factors. However, it is also
possible that there are true underlying gender differences in
the association between SDB and prediabetes. Sleep apnea
increases after menopause and can be reduced or alleviated
with hormone replacement therapy [30–32]. In addition
snoring was reported to increase during pregnancy [33,
34]. Similar gender differences were previously reported in
studies investigating SDB and diabetes [11, 35]. However, to
our knowledge; this is the first study analyzing the association
between SDB and prediabetes by gender.
Similarly, in subgroup analysis by race/ethnicity, the
association between SDB and prediabetes was present among
non-Hispanic whites and Mexican Americans/others, while
the association was absent in non-Hispanic blacks. It is
known that non-Hispanic blacks have a higher incidence of
diabetes [36]. Moreover, non-Hispanic blacks are known to
have higher prevalence of reduced sleep duration [37]. The
underlying mechanism for the lack of association between
SDB and prediabetes in non-Hispanic blacks remains
unclear. Non-Hispanic blacks have higher BMI [38], higher
rates of hypertension, and decreased physical activity [39],
and it is possible that these traditional risk factors may
explain most of the diabetes risk in non-Hispanic blacks than
SDB. There is a need for more prospective studies to examine
the association between markers of SDB and prediabetes by
race/ethnicity to prove or disprove our findings.
Several mechanisms have been proposed to explain the
association between SDB and prediabetes. Elevations in
evening cortisol concentrations and increased sympathetic
activity as result of short sleep duration were found to
predispose to insulin resistance [40]. The increase in the
sympathetic activity due to sleep deprivation, daytime
sleeping, and snoring is also associated with a decrease
in glucose tolerance through an inhibitory effect on the
pancreatic functions [41]. In addition, alterations in leptin
secretion and elevated ghrelin in sleep-deprived subjects
were reported to contribute to impaired glucose tolerance
and insulin resistance through weight gain [13, 42–44].
However, in the current study, the association between short
sleep duration and prediabetes remained significant even
after adjustment for BMI and waist circumference suggesting
that there probably are mechanisms other than weight gain
present in the association between short sleep duration and
prediabetes. Furthermore, experimental studies have shown
that reduced sleep is associated with increased levels of
inflammatory markers such as tumor necrosis factor alpha,
interleukin 6, and C-reactive protein [20, 45]. Inflammation
has in turn been shown to predict type 2 diabetes [46,
47]. Snoring and associated sleep apnea may play a role
in the development of insulin resistance through increased
catecholamine and cortisol levels [48–50]. For daytime
sleeping, the increased sympathetic activity on awakening
from naps results in activation of the renin-angiotensin
system, which is suggested to modulate insulin resistance and
associated hyperglycemia [51, 52].
This study has numerous strengths. Ours is one of the
few studies investigating the relationship between markers
of SDB and prediabetes. In addition, to our knowledge, this
is the first study analyzing the association between SDB and
prediabetes by gender and race/ethnicity. Moreover, the large
national sample of racially and ethnically diverse subjects
and the ability to adjust for numerous potential confounders
add to the strengths of the study. However, the study has
some limitations worth mentioning. First, the cross-sectional
nature of the study limits making conclusion regarding
the temporal association between SDB and prediabetes. In
addition, markers of SDB were self-reported and this might
have resulted in a misclassification bias.
In conclusion, in a nationally representative sample of
adults who were free of diabetes, we found that markers
of SDB were associated with prediabetes independent of
confounders, such as age, gender, BMI, and other factors.
This association was stronger in women and present mainly
in non-Hispanic whites and Mexican Americans.
Authors’ Contribution
All the authors contributed to the intellectual development of
this paper. O. Alshaarawy wrote the paper and was involved
in statistical analysis. S. Teppala performed the statistical
analyses and was involved in critical corrections of the
manuscript. A. Shankar had the original idea for the study,
supervised the statistical analysis and was involved in critical
corrections of the paper.
Conflict of Interests
There is no conflict of interests related to this paper.
Acknowledgments
This paper was funded by an American Heart Association
National Clinical Research Program Grant (A. Shankar) and
NIH/NIEHS Grant nos.1R03ES018888-01 (A. Shankar) and
5R03ES01888-02.
References
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